Disease-A-Month
Volume 53, Issue 5 , Pages 302-308 , May 2007

Cognitive Disturbances in Parkinson’s Disease

References 

  1. Cummings JL. Intellectual impairment in Parkinson’s disease: clinical, pathologic, and biochemical correlates. J Geriatr Psychiatry Neurol. 1988;1:24–36
  2. Aarsland D, Andersen K, Larsen JP, et al. Risk of dementia in Parkinson’s disease: a community based prospective study. Neurology. 2001;56:730–736
  3. Mayeux R, Denaro J, Hemenegildo N, et al. A population-based investigation of Parkinson’s disease with and without dementia: relationship to age and gender. Arch Neurol. 1992;49:492–497
  4. Reid WG, Hely MA, Morris JG, et al. A longitudinal study of Parkinson’s disease: clinical and neuropsychological correlates of dementia. J Clin Neuroci. 1996;3:327–333
  5. Rashkin SA, Borod JC, Tweedy J. Neuropsychological aspects of Parkinson’s disease. Neuropsychol Rev. 1990;1:185–219
  6. Bissesser S, Tissingh G, Wolters EC. CBF SPECT in Parkinson’s disease patients with mental dysfunction. J Neural Transm Suppl. 1997;50:25–30
  7. Firbank MJ, Colloby SJ, Burn DJ, et al. Regional Cerebral blood flow in Parkinson’s disease with and without dementia. Neuroimage. 2003;20:1309–1319
  8. Boeve BF, Silber MH, Ferman TJ. REM sleep behavior disorder in Parkinson’s disease and dementia with Lewy bodies. J Geriatr Psychiatry Neurol. 2004;17(3):146–157
  9. Hurtig HI, Trojanowski JQ, Galvin J, et al. Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson’s disease. Neurology. 2000;54:1916–1921
  10. Perry EK, Kilford L, Lees AJ, et al. Increased Alzheimer Pathology in Parkinson’s Disease related to antimuscarinic drugs. Ann Neurol. 2003;54(2):144–146
  11. Candy JM, Perry RH, Perry EK, et al. Pathological changes in the nucleus of Maynert in Alzheimer’s and Parkinson’s disease. J Neurol Sci. 1983;59:277–289
  12. Mattila PM, Roytta M, Lonnberg P, et al. Choline acetyltransferase activity and striatal dopamine receptors in Parkinson’s disease in relation to cognitive impairment. Acta Neuropathol. 2001;102:160–166
  13. Aarsland D, Larsen JP, Janvin C, et al. Donepezil treatment in Pakinson’s disease with dementia; a double blind, placebo-controlled crossover study. J Neurol Neurosurg Psychiatry. 2002;72:708–712
  14. Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson’s disease. N Engl J Med. 2004;351(24):2547–2549
  15. McKeith I, Del Ser T, Spano P-F, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomized, double blind, placebo controlled international study. Lancet. 2000;356:2031–2036
  16. Levy G, Tang MX, Cote LJ, et al. Motor impairment in PD: relationship to incident dementia and age. Neurology. 2000;55:539–544

PII: S0011-5029(07)00010-7

doi: 10.1016/j.disamonth.2007.02.007

Disease-A-Month
Volume 53, Issue 5 , Pages 302-308 , May 2007

Article Tools

* Image Usage & Resolution